Skip to Content

View Additional Section Content

GY012 - A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT03660826

Clinical Trial Categories

  • Corpus Uterus/Endometrial Cancer
Contact
Ashley Douglas, RN at 215-481-4429

Location

  • Asplundh Cancer Pavilion
    3941 Commerce Ave.
    Willow Grove, PA 19090

Find a Physician
Search Our Directory

215-481-MEDI
215-481-6334

Schedule a
Test

215-481-EXAM
215-481-3926